Haemonetics' Strategic Moves Poised To Boost Margins And Earnings, Says Analyst
Portfolio Pulse from Lekha Gupta
Needham & Co. analyst Mike Matson upgraded Haemonetics Corporation (NYSE:HAE) from Hold to Buy with a price target of $112, citing improved product mix and margin expansion. The analyst expects HAE to achieve a 27%+ operating margin by FY26, driven by higher-margin Interventional Technologies sales and reduced lower-margin Plasma sales to CSL. Investors can gain exposure via Neuberger Berman Small-Mid Cap ETF (NYSE:NBSM) and SPDR S&P Health Care Equipment (NYSE:XHE). HAE shares are up 4.55% at $87.21.
June 12, 2024 | 5:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham & Co. upgraded Haemonetics (HAE) from Hold to Buy with a price target of $112, driven by improved product mix and margin expansion. The analyst expects HAE to achieve a 27%+ operating margin by FY26.
The upgrade from Hold to Buy and the increased price target to $112 are strong positive signals. The analyst's confidence in margin expansion and improved product mix further supports a positive short-term impact on HAE's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Investors can gain exposure to Haemonetics (HAE) through Neuberger Berman Small-Mid Cap ETF (NBSM). The positive outlook on HAE could benefit NBSM.
As NBSM holds HAE, the positive outlook and upgrade of HAE could have a beneficial impact on NBSM's performance.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
Investors can gain exposure to Haemonetics (HAE) through SPDR S&P Health Care Equipment (XHE). The positive outlook on HAE could benefit XHE.
As XHE holds HAE, the positive outlook and upgrade of HAE could have a beneficial impact on XHE's performance.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50